Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Non-Current Debt (2016)

Dare Bioscience's Non-Current Debt history spans 4 years, with the latest figure at $4.4 million for Q4 2016.

  • For Q4 2016, Non-Current Debt fell 64.97% year-over-year to $4.4 million; the TTM value through Dec 2016 reached $4.4 million, down 64.97%, while the annual FY2016 figure was $4.4 million, 64.97% down from the prior year.
  • Non-Current Debt reached $4.4 million in Q4 2016 per DARE's latest filing, down from $6.6 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $13.6 million in Q1 2015 to a low of $587000.0 in Q3 2014.
  • Average Non-Current Debt over 4 years is $7.2 million, with a median of $7.6 million recorded in 2016.
  • Peak YoY movement for Non-Current Debt: surged 1693.87% in 2015, then tumbled 64.97% in 2016.
  • A 4-year view of Non-Current Debt shows it stood at $3.1 million in 2013, then crashed by 81.21% to $587000.0 in 2014, then skyrocketed by 2058.77% to $12.7 million in 2015, then crashed by 64.97% to $4.4 million in 2016.
  • Per Business Quant, the three most recent readings for DARE's Non-Current Debt are $4.4 million (Q4 2016), $6.6 million (Q3 2016), and $8.6 million (Q2 2016).